(Q35557492)

8 August 2017

0 references

1 reference

title

Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

Bin Wang

1

1 reference

8 August 2017

Fang Wang

2

1 reference

8 August 2017

Yue Zhang

3

1 reference

8 August 2017

Shi-Hua Zhao

4

1 reference

8 August 2017

Wen-Juan Zhao

5

1 reference

8 August 2017

Sheng-Li Yan

6

1 reference

8 August 2017

Yan-Gang Wang

7

1 reference

8 August 2017

6 February 2015

1 reference

The Lancet: Diabetes & Endocrinology

8 August 2017

1 reference

8 August 2017

3

1 reference

8 August 2017

4

1 reference

8 August 2017

263-274

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

8 August 2017

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

1 reference

7 January 2021

Sex- and age-specific prevalence and incidence rates of sight-threatening diabetic retinopathy in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Global prevalence and major risk factors of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

1 reference

7 January 2021

Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Incidence of Diabetic Retinopathy and Relationship to Baseline Plasma Glucose and Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effects of medical therapies on retinopathy progression in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

The Combination of Estimates from Different Experiments

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Network meta-analysis for indirect treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Evaluation of networks of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Bayesian methods for evidence synthesis in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Renal and retinal effects of enalapril and losartan in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Oxidative stress and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Oxygen delivery, consumption, and conversion to reactive oxygen species in experimental models of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970256-6

7 January 2021

10.1016/S2213-8587(14)70256-6

Identifiers

DOI

1 reference

8 August 2017

1 reference